AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27744447 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 102
Study 24937025 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (400-4,800 IU/d) with calcium intake of approximately 1,200 mg/day
Number of subjects: 163
Study 24937025 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 163
Study 23480554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin (0.5 mg + 0.02 mg/kg/d)
Number of subjects: 77
Study 23480554 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 23480554 — intervention group
Group type: EXPERIMENTAL
Intervention: Lutein and zeaxanthin
Number of subjects: 77
Study 20202178 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated whole blood processing system
Number of subjects: 0
Study 20202178 — intervention group
Group type: COMPARATOR
Intervention: Manual blood processing methods
Number of subjects: 0
Study 18346293 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg memantine for 12 weeks
Number of subjects: 19
Study 16325044 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson 400 microg
Number of subjects: 36
Study 16325044 — intervention group
Group type: EXPERIMENTAL
Intervention: Regadenoson 500 microg
Number of subjects: 36
Study 16325044 — intervention group
Group type: COMPARATOR
Intervention: Adenosine (control)
Number of subjects: 36
Study 12452211 — intervention group
Group type: COMPARATOR
Intervention: Double-blind, placebo-controlled food challenges (DBPCFC) with banana
Number of subjects: 4
Study 12452211 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick tests (SPTs) with banana
Number of subjects: 4
Study 12452211 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoblot analysis
Number of subjects: 4
Study 10353504 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaw relaxation
Number of subjects: 500
Study 10353504 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 500
Study 10353504 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of relaxation and music
Number of subjects: 500
Study 10353504 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 500
Study 7548701 — intervention group
Group type: EXPERIMENTAL
Intervention: Peto‐Peto‐Prentice Wilcoxon statistic
Number of subjects: 0
Study 7548701 — intervention group
Group type: COMPARATOR
Intervention: Logrank statistic
Number of subjects: 0
Study 1782932 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (TNG) patch (10 mg.24 h‐1) with a daily overnight 8‐h free interval
Number of subjects: 96
Study 1782932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 7047190 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (Positive End Expiratory Pressure)
Number of subjects: 8
Study 7047190 — intervention group
Group type: COMPARATOR
Intervention: ZEEP (Zero End Expiratory Pressure)
Number of subjects: 8
Study 31326277 — intervention group
Group type: EXPERIMENTAL
Intervention: AOS grading method
Number of subjects: 56
Study 31326277 — intervention group
Group type: COMPARATOR
Intervention: Efron grading method
Number of subjects: 56
Study 31326277 — intervention group
Group type: COMPARATOR
Intervention: CCLRU grading method
Number of subjects: 56
Study 31326277 — intervention group
Group type: EXPERIMENTAL
Intervention: Objective grading method
Number of subjects: 56
Study 30406392 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (400 mg thrice/day for 2 weeks)
Number of subjects: 23
Study 30406392 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin
Number of subjects: 23
Study 30406392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 27740850 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiperspirant
Number of subjects: 20
Study 27740850 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunscreen B (inorganic physical sun block)
Number of subjects: 20
Study 27740850 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen A (organic chemical sun filter)
Number of subjects: 20
Study 27740850 — intervention group
Group type: COMPARATOR
Intervention: No lotion
Number of subjects: 20
Study 24263176 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 100 mg twice daily for 28 days
Number of subjects: 76
Study 24263176 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 76
Study 24263176 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine hydrochloride 100 mg twice daily for 28 days (excluding minimal to no baseline aggression)
Number of subjects: 76
Study 24263176 — intervention group
Group type: COMPARATOR
Intervention: Placebo (excluding minimal to no baseline aggression)
Number of subjects: 76
Study 23449748 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin 4-mg capsules + splinting
Number of subjects: 63
Study 23449748 — intervention group
Group type: COMPARATOR
Intervention: Placebo + splinting
Number of subjects: 63
Study 20169378 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical massage (biweekly 30‐min sessions for 5 weeks)
Number of subjects: 34
Study 20169378 — intervention group
Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 34
Study 18395477 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10mg-80mg) for 6 months
Number of subjects: 97
Study 18395477 — intervention group
Group type: COMPARATOR
Intervention: Control group (52 age- and sex-matched healthy individuals)
Number of subjects: 97
Study 15359265 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac (0.5%)
Number of subjects: 37
Study 15359265 — intervention group
Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 37
Study 12432669 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to preferred music while out of restraints
Number of subjects: 40
Study 12432669 — intervention group
Group type: COMPARATOR
Intervention: No music while out of restraints
Number of subjects: 40
Study 10933357 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder distention in group 1 (no pretreatment)
Number of subjects: 40
Study 10933357 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder distention in group 2 (pretreatment with doxazosin, 2 mg)
Number of subjects: 40
Study 10933357 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin administration after bladder distention
Number of subjects: 40
Study 8661952 — intervention group
Group type: EXPERIMENTAL
Intervention: AAA Ca (900 mg/day)
Number of subjects: 58
Study 8661952 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (900 mg/day)
Number of subjects: 58
Study 8661952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 8661952 — intervention group
Group type: COMPARATOR
Intervention: AAA Ca (after switching from placebo)
Number of subjects: 58
Study 1645104 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.32 mg/70 kg triazolam
Number of subjects: 4
Study 1645104 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose-filled capsules)
Number of subjects: 4
Study 1645104 — intervention group
Group type: COMPARATOR
Intervention: Novel visual stimulus in the context of placebo
Number of subjects: 4
Study 6387488 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily administration of an agonist of gonadotropin‐releasing hormone
Number of subjects: 8
Study 30715168 — intervention group
Group type: EXPERIMENTAL
Intervention: pemetrexed and a platinum-based chemotherapy (cisplatin or carboplatin) plus 200 mg of pembrolizumab every 3 weeks for 4 cycles, followed by pembrolizumab for up to a total of 35 cycles plus pemetrexed maintenance therapy
Number of subjects: 0
Study 30715168 — intervention group
Group type: EXPERIMENTAL
Intervention: carboplatin or cisplatin with pemetrexed and atezolizumab followed by maintenance pemetrexed and atezolizumab
Number of subjects: 0
Study 30715168 — intervention group
Group type: EXPERIMENTAL
Intervention: atezolizumab/carboplatin/nab-P
Number of subjects: 0
Study 30715168 — intervention group
Group type: EXPERIMENTAL
Intervention: carboplatin/nab-P
Number of subjects: 0
Study 30715168 — intervention group
Group type: COMPARATOR
Intervention: nab-PC regimen
Number of subjects: 0
Study 29177501 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine
Number of subjects: 400
Study 29177501 — intervention group
Group type: EXPERIMENTAL
Intervention: Prilocaine + Bupivacaine
Number of subjects: 400
Study 27824231 — intervention group
Group type: EXPERIMENTAL
Intervention: FITSTART intervention
Number of subjects: 331
Study 27824231 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 331
Study 1358830 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 21
Study 1358830 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 21
Study 1358830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 22068424 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy Vax™ dermal electroporation system (administered in two areas, total of six doses)
Number of subjects: 10
Study 22068424 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy Vax™ dermal electroporation system (administered in deltoid regions only after initial complaints)
Number of subjects: 10
Study 22068424 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy Vax™ dermal electroporation system (measured electrical properties of the skin)
Number of subjects: 10
Study 21118176 — intervention group
Group type: EXPERIMENTAL
Intervention: Short program of medium intensity physical training (45-60 min, 3 times/week, 50-60% of VEM-test workload)
Number of subjects: 100
Study 21118176 — intervention group
Group type: EXPERIMENTAL
Intervention: Short program of medium intensity physical training
Number of subjects: 100
Study 21118176 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard therapy for EVI treatment of IHD)
Number of subjects: 100
Study 18509971 — intervention group
Group type: COMPARATOR
Intervention: Treatment 1: Oral MgSO4 solution before operation, Cefradine 2.0 g (I.V.) during anesthesia induction, followed by two doses of Cefradine 2.0 g and 0.5% Metronidazole 100 ml at 12-hour intervals for 24 hours post-operation.
Number of subjects: 165
Study 18509971 — intervention group
Group type: COMPARATOR
Intervention: Treatment 2: Same as Treatment 1, but antibiotics continued for 3-5 days post-operation.
Number of subjects: 165
Study 18509971 — intervention group
Group type: COMPARATOR
Intervention: Control: Oral antibiotics 2-3 days before operation.
Number of subjects: 165
Study 15974371 — intervention group
Group type: EXPERIMENTAL
Intervention: STEP program (intervention group)
Number of subjects: 0
Study 15974371 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12687748 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive exchange transfusion
Number of subjects: 39
Study 12687748 — intervention group
Group type: COMPARATOR
Intervention: Conservative (simple) transfusion
Number of subjects: 39
Study 10588553 — intervention group
Group type: EXPERIMENTAL
Intervention: Double injection (group 2)
Number of subjects: 50
Study 10588553 — intervention group
Group type: COMPARATOR
Intervention: Single injection (group 1)
Number of subjects: 50
Study 8676720 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO
Number of subjects: 185
Study 8676720 — intervention group
Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 185
Study 1873582 — intervention group
Group type: EXPERIMENTAL
Intervention: Stomatognathic treatment and biofeedback therapy
Number of subjects: 32
Study 6385318 — intervention group
Group type: EXPERIMENTAL
Intervention: HFJV/CPAP + IMV (1)
Number of subjects: 16
Study 6385318 — intervention group
Group type: EXPERIMENTAL
Intervention: HFJV/CPAP + IMV (2)
Number of subjects: 16
Study 6385318 — intervention group
Group type: COMPARATOR
Intervention: HFJV/CPAP
Number of subjects: 16
Study 31842784 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted/standard laparoscopic rectal cancer surgery after 8 weeks
Number of subjects: 340
Study 31842784 — intervention group
Group type: COMPARATOR
Intervention: Robotic-assisted/standard laparoscopic rectal cancer surgery after 12 weeks
Number of subjects: 340
Study 30899948 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS nursing after operation
Number of subjects: 90
Study 26879276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 0.5 mg
Number of subjects: 258
Study 26879276 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozanimod 1 mg
Number of subjects: 258
Study 26879276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 24585721 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC + zoledronic acid (ZA) 4 mg i.v. every 3 weeks
Number of subjects: 96
Study 24585721 — intervention group
Group type: COMPARATOR
Intervention: TAC (docetaxel, adriamycin, and cyclophosphamide)
Number of subjects: 96
Study 24585721 — intervention group
Group type: EXPERIMENTAL
Intervention: TAC + ZA
Number of subjects: 96
Study 24585721 — intervention group
Group type: COMPARATOR
Intervention: TAC
Number of subjects: 96
Study 23128568 — intervention group
Group type: EXPERIMENTAL
Intervention: Values-affirmation exercise
Number of subjects: 99
Study 23128568 — intervention group
Group type: COMPARATOR
Intervention: Control exercise
Number of subjects: 99
Study 20573081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 50 microg
Number of subjects: 12
Study 20573081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 300 microg
Number of subjects: 12
Study 20573081 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 600 microg
Number of subjects: 12
Study 20573081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17426604 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) (N=10)
Number of subjects: 22
Study 17426604 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) (N=12)
Number of subjects: 22
Study 17556612 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins (B, C, and E)
Number of subjects: 829
Study 17556612 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A and beta-carotene (VA/BC)
Number of subjects: 829
Study 17556612 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamins including VA/BC
Number of subjects: 829
Study 17556612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 829
Study 15562085 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50
Study 15562085 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 50
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0625 mg/d GnRH antagonist
Number of subjects: 329
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125 mg/d GnRH antagonist
Number of subjects: 329
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 mg/d GnRH antagonist
Number of subjects: 329
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/d GnRH antagonist
Number of subjects: 329
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 mg/d GnRH antagonist
Number of subjects: 329
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 mg/d GnRH antagonist
Number of subjects: 329
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: FSH levels
Number of subjects: 329
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: Late follicular phase LH, AD, and E(2) levels
Number of subjects: 329
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: Late follicular phase E(2) levels
Number of subjects: 329
Study 11287020 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing GnRH antagonist doses
Number of subjects: 329
Study 9103484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone phenylpropionate (group 1, n = 7)
Number of subjects: 23
Study 9103484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (group 2, n = 6) injected into gluteal muscle in 4 ml of arachis oil
Number of subjects: 23
Study 9103484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (group 3, n = 5) in 1 ml of arachis oil injected into gluteal muscle
Number of subjects: 23
Study 9103484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (group 4, n = 5) in 1 ml of arachis oil injected into deltoid muscle
Number of subjects: 23
Study 9103484 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate 1-ml gluteal injection
Number of subjects: 23
Study 7799411 — intervention group
Group type: EXPERIMENTAL
Intervention: Urease test for Helicobacter pylori detection
Number of subjects: 244
Study 3733274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone (2 g i.v.) with frusemide (40 mg p.o.)
Number of subjects: 12
Study 3733274 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (2 g i.v.) with placebo
Number of subjects: 12
Study 31142636 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 50
Study 28417592 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (50-700 mg daily)
Number of subjects: 81
Study 28417592 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram based on allopurinol dose-response relationship
Number of subjects: 81
Study 25176167 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram plus psychotherapy treatment for the depressed cohort
Number of subjects: 67
Study 25176167 — intervention group
Group type: COMPARATOR
Intervention: Citalopram treatment
Number of subjects: 67
Study 23649140 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 IU Vitamin D (Group A)
Number of subjects: 4
Study 23649140 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 IU Vitamin D (Group B)
Number of subjects: 4
Study 23649140 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 IU Vitamin D (Group C)
Number of subjects: 4
Study 23649140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Group D)
Number of subjects: 4
Study 21885884 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily weather conditions (temperature, rainfall, snowfall, daylight hours)
Number of subjects: 241
Study 21885884 — intervention group
Group type: EXPERIMENTAL
Intervention: Weather conditions
Number of subjects: 241
Study 19468961 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied to PC 3 using a 5-V pulse at 10 Hz for 15 minutes.
Number of subjects: 24
Study 19468961 — intervention group
Group type: COMPARATOR
Intervention: Non-meridian control area (no EA applied).
Number of subjects: 24
Study 16705847 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus point-injection at points Quchi (LI11), Xuehai (SP10), Zusanli (ST36), Sanyinjiao (SP6), and Fengchi (GB20) plus point-injection at Zusanli (ST36) and Quchi (LI11)
Number of subjects: 64
Study 16705847 — intervention group
Group type: COMPARATOR
Intervention: Antihistamines (Acrivastine, Cinnarizine, Ranitidine)
Number of subjects: 64
Study 15346264 — intervention group
Group type: COMPARATOR
Intervention: Thalidomide monotherapy (n = 38)
Number of subjects: 63
Study 15346264 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide combined with chemotherapy (n = 25)
Number of subjects: 63
Study 11602481 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave treatment (ESWT)
Number of subjects: 60
Study 11602481 — intervention group
Group type: COMPARATOR
Intervention: Simulated treatment (shocks of 0 mJ/mm(2) energy)
Number of subjects: 60
Study 9810943 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine injections
Number of subjects: 49
Study 9810943 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine infusions
Number of subjects: 49
Study 9810943 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine injections and infusions
Number of subjects: 49
Study 9810943 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous apomorphine
Number of subjects: 49
Study 8206677 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 (protocol 1, 40 patients)
Number of subjects: 73
Study 8206677 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 plus interferon-gamma (IFN-gamma) (protocol 2, 33 patients)
Number of subjects: 73
Study 8206677 — intervention group
Group type: COMPARATOR
Intervention: IL-2 alone (protocol 1)
Number of subjects: 73
Study 8206677 — intervention group
Group type: COMPARATOR
Intervention: IL-2 plus IFN-gamma (protocol 2)
Number of subjects: 73
Study 8206677 — intervention group
Group type: COMPARATOR
Intervention: Pre-treatment sTNF-alpha R concentration
Number of subjects: 73
Study 2919468 — intervention group
Group type: EXPERIMENTAL
Intervention: Copeland electrodes
Number of subjects: 0
Study 2919468 — intervention group
Group type: COMPARATOR
Intervention: Spiral electrodes
Number of subjects: 0
Study 31658624 — intervention group
Group type: EXPERIMENTAL
Intervention: m-Health intervention targeting physical activity, diet, and sleep quality
Number of subjects: 40
Study 31658624 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 40
Study 27725164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 10 mg twice daily for 7 days
Number of subjects: 56
Study 27725164 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 26342236 — intervention group
Group type: EXPERIMENTAL
Intervention: Molecularly targeted agents (experimental group)
Number of subjects: 195
Study 26342236 — intervention group
Group type: COMPARATOR
Intervention: Treatment at physician's choice (control group)
Number of subjects: 195
Study 26342236 — intervention group
Group type: COMPARATOR
Intervention: Cytotoxic chemotherapy (control group)
Number of subjects: 195
Study 24292815 — intervention group
Group type: EXPERIMENTAL
Intervention: docetaxel, anthracycline, and cyclophosphamide (TEC)
Number of subjects: 96
Study 24292815 — intervention group
Group type: COMPARATOR
Intervention: docetaxel plus cyclophosphamide (TC)
Number of subjects: 96
Study 21632605 — intervention group
Group type: EXPERIMENTAL
Intervention: Small priming dose of etomidate (0.03 mg kg(‐1))
Number of subjects: 80
Study 21632605 — intervention group
Group type: COMPARATOR
Intervention: Lipid emulsion placebo
Number of subjects: 80
Study 19669786 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant cocktail (AOC; vitamins C, E, and alpha-lipoic acid)
Number of subjects: 14
Study 19669786 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min forearm occlusion
Number of subjects: 14